P-GSK-3β (Ser9) was significantly low-expressed in the PD model group compared with the control group (P < 0.01), and this decreased expression was increased in the PD + CFR treatment group (P < 0.01); compared with the control group, P-GSK-3β (Tyr216) expression was significantly increased in the PD model group (P < 0.01), and this expression level was inhibited in the PD + CFR treatment group (P < 0.05). This evidence concerns the gene GSK3B and Parkinson disease.